Daiichi Sankyo Begins Patient Dosing In Tropion-Lung07 Phase 3 Trial To Evaluate Datopotamab Deruxtecan In Combo With Pembrolizumab To Treat Patients With Previously Untreated Metastatic Nsclc

Daiichi Sankyo Begins Patient Dosing In Tropion-Lung07 Phase 3 Trial To Evaluate Datopotamab Deruxtecan In Combo With Pembrolizumab To Treat Patients With Previously Untreated Metastatic Nsclc

By, Admin 1 February 2023

Daiichi Sankyo Announced That The First Patient Has Been Dosed In The Global, Randomized Tropion-Lung07 Phase 3 Trial Evaluating Datopotamab Deruxtecan (Dato-Dxd) In Combination With Pembrolizumab With Or Without Platinum Chemotherapy, In Patients With Previously Untreated Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Nsclc) With Pd-L1 Expression Less Than 50% (Tps<50%) And Without Actionable Genomic Alterations.Datopotamab Deruxtecan Is A Specifically Engineered Trop2 Directed Dxd Antibody Drug Conjugate (Adc) Being Jointly Developed By Daiichi Sankyo And Astrazeneca.Among Patients With Nsclc, Nearly Half Are Diagnosed At An Advanced Stage And Generally Have A Poor Prognosis. While First-Line Treatment With Pembrolizumab Or Other Checkpoint Inhibitors, With Or Without Chemotherapy, Has Improved Outcomes In Patients With Nsclc Without Actionable Genomic Alterations, Disease Progression Still Occurs In The Majority Of Patients.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!